期刊文献+

颈动脉粥样硬化斑块患者血清基质金属蛋白酶9的表达及意义 被引量:1

Expression and significance of serum matrix metanoproteinase-9 in patients with carotid atherosclerosis plaques
下载PDF
导出
摘要 目的探讨颈动脉粥样硬化斑块与血清基质金属蛋白酶9(MMP-9)水平的关系。方法选取30例经彩色多普勒超声证实存在颈动脉粥样硬化斑块的患者为研究组,其中稳定斑块18例,不稳定斑块12例,30例健康查体者为对照组。均抽取空腹血应用酶联免疫吸附法检测血清MMP09水平。结果研究组的MMP-9表达为(295.34±126.76)μg/L,明显高于对照组的(98.38±34.57)μg/L(t=4.835,P〈0.05);研究组稳定斑块患者中MMP-9的表达为(267.45±113.86)μg/L,明显低于不稳定斑块患者的(498.57±142.68)μg/L(t=3.768,P〈0.05)。结论血清MMP-9水平与颈动脉粥样硬化斑块形成有关,可以反映颈动脉粥样硬化斑块的稳定性。 Objective To investigate the relationship between the carotid atherosclemsis plaques and the serum matrix metalloproteinase-9 (MMP-9) level. Methods Thirty patients with carotid atherosclerotic plaques confirmed by color Doppler ultrasound was as the study group( stable plaque 18 cases and unstable plaque 12 cases) ,30 cases of healthy people was as control group. Fasting blood samples were taken to measure the levels of serum MMP-9. Results In the control group, the expression of MMP-9 (98.38 ± 34.57)μg/L was significantly lower than that in the study group[ (295.34 ± 126.76) μg/L]. In the stable plaque group,the expression of MMP-9 was significantly lower than that in the unstable plaque group[ (267.45 ± 113.86)μg/L vs (498.57 ± 142.68) μg/L] (t = 3. 768 ,P 〈 0. 05 ). Conclusion The serum MMP-9 levels are related with the carotid atherosclerotic plaque formation and reflect the stability of the carotid atherosclerotic plaque.
出处 《中国医药》 2011年第11期1361-1362,共2页 China Medicine
关键词 动脉粥样硬化 颈动脉 斑块 基质金属蛋白酶9 Atherosclerosis Carotid artery Plaque Matrix metallopmteinase-9
  • 相关文献

参考文献12

二级参考文献106

共引文献76

同被引文献37

  • 1Liu P, Sun M, Sader S. Matrix metalloproteinases in cardiovascular disease [ J ]. Can J Cardiol,2006,22 (Suppl B) :25 B-30B.
  • 2Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease [J]. Biochem Pharmacol,2008,75 (2) :346-359.
  • 3Brew K, Nagase H. The tissue inhibitors of metalloproteinases (TIMPs) :an ancient family with structural and functional diversity [J]. Biochim Biophys Acta,2010,1803( 1 ) :55-71.
  • 4Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases : evolution, structure and function [ J ]. Biochim Biophys Acta,2000,1477 (1-2) :267-283.
  • 5Hwang JJ, Yang WS, Chiang FT, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease [J]. Atherosclerosis, 2009,204 (1):293- 297.
  • 6Tanindi A, Sahinarslan A, Elbeg S, et al. Relationship between MMP-1, MMP-9, TIMP-1, IL-6 and risk factors, clinical presentation, extent and severity of atherosclerotic coronary artery disease [J]. Open Cardiovasc Med J,2011,5 :110-116.
  • 7Kimura K, Cheng XW, Nakamura K, et al. Matrix metalloproteinase-2 regulates the expression of tissue inhibitor of matrix metalloproteinase-2 [J]. Clin Exp Pharmacol Physiol, 2010, 37 ( 11 ) :1096-1101.
  • 8Ebrahem Q, Qi JH, Sugimoto M, et al. Increased neovascularization in mice lacking tissue inhibitor of metalloproteinases-3 [ J]. Invest Ophthalmol Vis Sci,2011,52(9) :6117-6123.
  • 9Mukherjee R, Herron AR, Lowry AS, et al. Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventrieular myoeardium in patients with atrial fibrillation [J]. Am J Cardiol,2006,97(4) :532-537.
  • 10Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclemsis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits [ J ]. Am J Pathol,2008,172 (5) : 1419-1429.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部